A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting

Phase 3

Sponsor:

Laboratoire français de Fractionnement et de Biotechnologies

Code:

NCT05695391

Conditions

Hemophilia

Eligibility Criteria

Sex: Male

Age: 12 - 65

Healthy Volunteers: Not accepted

Interventions

Coagulation Factor VIIa (Recombinant)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information